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ABSTRACT 
Objective: To evaluate the prenatal developmental toxicity of low molecular weight galactomannans based standardized fenugreek seed extract 
(LMWGAL-TF).  
Methods: Rats received oral administration of LMWGAL-TF (250, 500 and 1000 mg/kg) during the period of gestation from day 5 (implantation 
day)–19 (1 d before expected day of parturition) post conception. Maternal, embryo, and fetal toxicity parameters were evaluated.  
Results: LMWGAL-TF exposure did not produce maternal (clinical observations, body weight gain, food intake) and embryo–fetal toxicity. 
Occasional skeletal and visceral malformations, unrelated to the treatments, were seen in both LMWGAL-TF-treated and vehicle control (VC) 
groups.  
Conclusion: Oral exposure of LMWGAL-TF during the prenatal period did not induce significant maternal and embryo–fetal toxicity up to a dose of 
1000 mg/kg in rats. The dose of 1000 mg/kg was considered as NOAEL for LMWGAL-TF. 
Keywords: Developmental toxicity, Low molecular weight galactomannans, Standardized fenugreek seed extract, OECD Test No. 414, Reproductive 
system, Rat. 
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INTRODUCTION 
The increased use of botanicals or food supplements by consumers 
and industry has raised concerns among scientific and regulatory 
communities. Medicinal supplements from plants possess functional 
properties or health benefits. The sources of food supplement may 
vary from staple food plants to herbals used in folk medicine and 
comprise the whole plant, extracts thereof or purified components 
[1, 2]. The crude extracts of varieties of plants have been used in 
clinical practices from a long time [3] and often possess diversified 
phytoconstituents with unknown biological effects and can produce 
toxicity and drug interactions that harm to human health [4, 5]. 
There is a need for safety reports for a botanical extract of crude as 
well as purified fractions for their validated activities.  
Trigonella foenum-gracum (TF), known as fenugreek, is one of the 
most promising medicinal herbs, known from ancient times. 
Fenugreek seeds have known for many applications towards female 
health. In ancient Rome, fenugreek seeds were used to aid labor and 
delivery [6]. Fenugreek seeds or powder used by traditional 
Ayurvedic physicians to enhance milk production to breastfeeding 
mothers [6-8]. These benefits on female health have been attributed 
to unique dietary fiber components of fenugreek seeds [9]. The 
endosperm of the fenugreek seed is a rich source of fiber (20 %) and 
gum (32.4 %) [10-12], which include galactomannans (GAL). 
Fenugreek GAL is a group of oligosaccharides (OS) composed of 
mannose as the backbone with galactose as side groups in the ratio 
of 1:1.  
Fenugreek seeds contain both soluble and insoluble types of fibers 
[13]. The soluble dietary fiber content of fenugreek seeds is known 
to be responsible for health benefits such as effective restoration of 
both glucose and fat metabolism in DM [6, 14, 15]. The soluble 
dietary fiber fraction of fenugreek seeds of various compositions 
reported to have antidiabetic [16, 17], hypolipidemic [18, 19] and a 
food stabilizer properties [12].  
Soluble fiber fraction of fenugreek is rich in low molecular weight 
galactomannans (LMWGAL) containing oligosaccharides (OS) such 
as raffinose (three monosaccharide units) and stachyose (five 
monosaccharide units). LMWGAL from fenugreek seeds 
demonstrated anti-hyperglycemic [15] and anabolic potential in 
male rats [20] and against diet-induced obesity in C57/BL6 mice 
[21]. Furthermore, the clinical benefit of LMWGAL based 
standardized fenugreek seed extract on strength and body 
composition in resistance-trained males has been reported [22]. 
A crude form of fenugreek seed powder or extract was found to be 
safe in many prior studies [23, 24]. Oral exposure of LMWGAL-TF is 
reported to be safe during acute and subchronic toxicity studies in 
male and female rats [25] and during 8-weeks of exposure to 
resistance-trained male subjects [22]. However, the safety or toxicity 
information of LMWGAL-TF in females during the gestational period 
of pregnancy is not yet known. Looking at potential applications of 
LMWGAL-TF for the area of female health, the study involving 
prenatal exposure on reproduction related parameters in pregnant 
mothers and fetuses is necessary. Therefore, we undertook the 
present study to evaluate the effects of LMWGAL-TF on pregnant 
female rats and their fetuses during oral exposure to female rats 
during the period of gestation, beginning from the implantation day 
as per OECD 414 guidelines, an internationally accepted procedure. 
MATERIALS AND METHODS 
Animals 
Adult and young nulliparous and non-pregnant healthy female 
Wistar rats (of 14-15 w) and adult, proven fertile male rats were 
inbred at the lab of INTOX Private Limited, Pune, India. Animals 
were housed in solid polypropylene cages with stainless steel grill 
tops and bedding of clean and sterilized paddy husk for at least eight 
days before mating. 'Nutrilab' brand extruded rodent pelleted feed 
(M/s Provimi Animal Nutrition India Pvt. Ltd., Bangalore) and 
filtered water were provided ad libitum. During the entire study, 
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animals were kept at the following controlled conditions: 
temperature of 22±2 °C, 50±20% of relative humidity, and a 
light/dark cycle of 12 h. Two females cohabited overnight with a 
male and examined for the presence of sperm in their vagina. The 
day that sperm was detected was defined as gestational day 0. After 
mating is confirmed, on '0' day, pregnant rats were housed 
individually and randomly assigned to the vehicle control (VC) and 
treatment groups. The study was conducted at INTOX Private 
Limited (Pune, India), a GLP Certified laboratory and with prior 
approval from Institutional Animal Ethics Committee (IAEC) in 
accordance with guidelines set by Committee Purpose of Control and 
Supervision of Experiments on Animals (CPCSEA), New Delhi, India.  
Chemicals 
The test compound, LMWGAL-TF, was supplied by Indus Biotech 
Private Limited (Pune, India) after preparation and characterization 
(HPLC and LC-MS) as per reported procedure [15]. LMWGAL-TF is 
standardized fenugreek seed extract (96.21 % water soluble low 
molecular weight galactomannans). LMWGAL-TF is available as 
Torabolic® as marketed dietary supplement. The LMWGAL-TF is 
water soluble powder. The fresh solution was prepared daily as 1% 
w/v in distilled water (vehicle) and administered once daily by oral 
route to rats in a volume of 5 ml/kg body weight. Dosing 
formulations were prepared appropriate concentrations as per 
study design to meet dosage level requirements.  
Methods 
The study was conducted in accordance with OECD Guidelines (Test 
No. 414: Prenatal Development Toxicity Study) [26]. Dose-range 
finding study was conducted before the main study. 
Dose-range finding study 
Female rats were cohabited with male rats (1 male: 2 females) 
overnight and examined for the presence of spermatozoa in vaginal 
smear next day morning. The day on which the sperms were found 
in the vagina was considered gestational day 0 (GD 0). Four groups 
of seven female rats each (‘0’ day pregnant) were administered with 
either vehicle or LMWGAL-TF (250 mg/kg, 500 mg/kg or 1000 
mg/kg) from GD5 to GD19 and checked for systemic toxicity, body 
weight, and food consumption. All dams were sacrificed on GD20 
and subjected to necropsy examination for ovaries and uterine 
contents. Fetal abnormalities were assessed by external 
examination. The highest dose level of 1000 mg/kg body weight did 
not result in any remarkable maternal or fetal toxicity in the exposed 
rats. Based on the findings, doses 250 mg/kg, 500 mg/kg and 1000 
mg/kg body weight were selected for the main study. 
Main study 
One hundred and twenty female rats (‘0’ day pregnant) were 
selected and randomized into 4 groups (n=30 in each group). The 
day on which the sperms were found in the vagina was considered 
GD0. The rats were gavaged daily from GD5 to GD19. Each group of 
rats was treated either with Vehicle (G1: VC) or LMWGAL-TF 
(G2:250 mg/kg, G3: 500 mg/kg or G4: 1000 mg/kg). Cage-side 
observations of females were conducted at least once daily. Food 
consumption was measured at 3 d intervals starting on GD5. 
Maternal body weights were recorded on GD 0, 5, 8, 11, 14, 17 and 
prior to their terminal sacrifice on day 20. All animals were 
sacrificed on GD 20 by CO2 asphyxiation. The uterus from each 
female was examined for the number and placement of uterine 
implantation sites, number of live and dead fetuses, number of early 
and late resorptions and any abnormalities of the uterus or 
embryonic sac. Dams were examined for the number of corpora 
lutea of ovaries. Sex and the body weight of each fetus were 
determined. Pre-implantation and post-implantation loss was 
calculated as follows: pre-implantations loss = [(no. of corpora lutea 
− no. of implantations)/no. of corpora lutea] × 100 and post-
implantation loss = [(no. of dead implants)/no. of total 
implantations] ×100 [27]. Uteri which had no visible implantation 
sites were stained with ammonium sulfide (10%) to detect very 
early resorptions [28]. All live fetuses were individually weighed, 
sexed, and examined for external anomalies in a uniform order 
(from head to tail) for external malformations. Live fetuses were 
euthanized by using diethyl ether vapors. One-half of the fetuses 
from each litter was selected in a random manner and subjected to 
visceral examination by Wilson's Technique for assessment of soft 
tissue development [29]. The remaining half number of the fetuses 
were sacrificed, eviscerated and processed for skeletal examination 
using Alizarin Red S staining method [30].  
Data analysis 
The data was presented as mean±standard deviation (SD). The litter 
was used as the basis for the analysis of fetal variables. Gestational 
body weights, corrected body weight, body weight gain and food 
consumption of pregnant rats, litter weight (total, male and female), 
average pup weight, uterus weight (absolute and relative), pre-
implantation loss (%), post-implantation loss (%), dead and live 
fetuses (%), were analyzed by one-way analysis of variance, 
followed by Dunnett’s test. Number of the male and female pup, sex 
ratio, the number of corpora lutea, the number of implantation, the 
number of live and dead fetuses, and the number of early and late 
resorptions and incidences of fetal visceral and skeletal 
malformations were evaluated by using the Kruskal–Wallis test, 
followed by the Mann–Whitney test. Numbers of pregnant and non-
pregnant females, the number of live and dead females were 
analyzed by using Fisher’s test. Treated groups were compared to 
VC. The results of the statistical analysis were assessed at 5% level 
of significance (p<0.05). 
RESULTS 
Maternal toxicity 
No mortality was observed in any of treatment groups during the 
study period. No evident clinical signs were observed in any dam 
during the study. The data related to maternal finding is presented 
in table 1. No abortion was observed in any of the dams during the 
study period. There was no significant difference in body weight 
gain of pregnant rats between LMWGAL-TF exposed groups and the 
VC group throughout the experimental period. There were no 
differences between the treatment groups and VC for the maternal 
weight and food consumption. No significant difference was found in 
the pregnancy rate of treatment groups of 250 (86.6%), 500 (96.6%) 
and 1000 (96.6%) mg/kg dose groups as compared to VC (86.6%). 
  
Table 1: LMWGAL-TF. Maternal findings 
Parameters G1 LMWGAL-TF treatment 
G2 G3 G4 
VC 250 mg/kg 500 mg/kg 1000 mg/kg 
Pregnancy data         
Initial animals per group 30 30 30 30 
Confirmed pregnancy at necropsy 26 26 29 29 
Pregnancy rate (%) 86.66 86.66 96.66 96.66 
Maternal data         
Body weight (g) GD5 214.69±12.76 212±12.47 215.69±12.51 211.55±11.19 
Final body weight (g)GD20 283.54±26.44 274.5±27.58 279.07±23.71 276.62±17.35 
Body weight change (g) during GD5 to GD20 68.85±16.00 62.5±19.77 63.38±19.76 65.07±12.56 
Corrected Body weight (g) 237.17±12.70 232.06±14.87 232.32±18.31 229.08±12.97 
Values are expressed as mean±SD. n = 30 female rats per group were randomized. VC-Vehicle control, GD-Gestational Day. 
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Table 2: LMWGAL-TF. Embryo–fetal toxicity related to reproductive findings 
Parameters G1 LMWGAL-TF treatment 
G2 G3 G4 
VC 250 mg/kg 500 mg/kg 1000 mg/kg 
Gravid uterus weight (g) 46.37±18.89 42.44±16.56 46.75±12.81 47.54±12.71 
Corpora lutea (No.) 10.85±1.91 9.73±2.16 9.93±1.87 10.14±1.36 
Implantations per female (No.) 9.12±3.00 8.46±3.11 8.72±2.19 9.00±1.63 
Early resorptions (No.) 0.50±1.14 0.54±0.71 0.48±1.02 0.52±1.09 
Late resorptions (No.) 0.04±0.20 0 0 0 
Pre-implantation loss (%)a 16.6±21.38 15.53±23.19 12.03±18.89 11.21±14.84 
Post-implantation loss (%)b 8.78±18.46 8.79±19.76 6.82±18.86 6.95±15.09 
Litter size (No.) 8.58±3.57 8.24±2.82 8.54±2.12 8.48±2.23 
Live fetuses (No.) 8.58±3.57 8.24±2.82 8.54±2.12 8.48±2.23 
Dead fetuses (No.) 0 0 0 0 
Live male fetuses (No.) 5.08±2.17 4.21±1.74 4.63±1.69 4.83±1.87 
Live female fetuses (No.) 3.88±2.07 4.20±1.94 4.38±1.83 3.66±1.65 
Male/female sex ratio (No.) 1.57±1.12 1.26±1.30 1.50±1.42 1.81±1.45 
Average fetal weight (g) 3.30±0.43 3.45±0.33 3.59±0.30 3.82±0.87* 
Average male  
fetal weight (g) 
3.47±0.32 3.60±0.31 3.69±0.31* 3.77±0.29* 
Average female  
fetal weight (g) 
3.20±0.46 3.33±0.37 3.46±0.33* 3.53±0.28* 
n = 30 female rats per group were randomized. Values are expressed as mean±SD, a[(Number of Corpora Lutea-Number of implantations)/Number 
of Corpora Lutea] × 100, b[(Number of dead implants)/Total number of implantations] × 100, *P<0,05 v/s. VC group. VC-Vehicle control. 
 
Table 3: LMWGAL-TF. Fetal malformations and variations 
Parameters G1 LMWGAL-TF treatment 
G2 G3 G4 
VC 250 mg/kg 500 mg/kg 1000 mg/kg 
Total no. fetuses (litters) examineda 
External 223 (26) 206 (26) 239 (29) 246 (29) 
Visceral 106 (25) 97 (24) 113 (28) 116 (29) 
Skeletal  117 (26) 109 (25) 126 (28) 130 (29) 
External Malformation 0 0 0 0 
Visceral variations 
Brain: Hydrocephalus  
of lateral ventricles (slight) 
0 1 (1) 1(1) 0 
Kidney: Hypoplasia (both) 0 0 1(1) 0 
Eye: Retinal folding (left) 0 0 1(1) 0 
Eye: Retinal folding (both) 0 0 1(1) 0 
Skeletal variations 




17 (7) 13(9) 19 (10) 14 (10) 
Un-ossified  12 (9) 16 (7) 10 (8) 4 (4) 
Spilt, rudimentary, dumbbell shaped,  
asymmetrical, misshapen,  
hyperplasia, extra  
29 (22) 31 (18) 28 (18) 26 (16) 
Rib Variations 
Rudimentary (14th-right/left/both) 22 (13) 37 (20) 34 (19) 34 (22) 
Extra/Accessory (right/left/both) 2 (2) 6 (6) 7 (7) 6 (6) 
Undulated, nodulated, short,  
asymmetrical, wavy, absent 
6 (6) 8 (5) 1 (1) 3 (3) 
Vertebrae variations 
Cervical: No/Poor ossification 3 (3) 0 0 0 
Sacral: No/Poor ossification 1 (1) 0 0 0 
Lumbar: Incomplete/ 
Poor ossification 
0 2 (2) 0 0 
Thoracic vertebra centra:  
Dumbbell shaped, spilt,  
asymmetrical, misshapen 
7 (7) 14 (3) 15 (7) 14 (11) 
Sacral: Fused 0 0 1 (1) 0 
Limb Variations 
Fore limb: Fingers misshapen 0 0 0 1(1) 
Fetuses from pregnant female rats per group were examined. a The incidence of the individual defect is presented as a number of fetuses (numbers 
of litters). VC-Vehicle control 
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Reproductive findings related to embryo–fetal toxicity 
The data of embryo–fetal toxicity related to reproductive findings 
are presented in table 2. The gravid uteri of females sacrificed on 
GD20 did not reveal any remarkable alterations indicative of adverse 
effects of LMWGAL-TF. There was no significant difference in a 
number of corpora lutea, live fetuses, and implantation sites, early 
and late resorption, pre-and post-implantation loss in LMWGAL-TF 
treated groups as compared to VC group.  
The fetal weights of male and female fetuses in LMWGAL-TF (500 and 
1000 mg/kg) were significantly (P<0.05) more than that of VC groups. 
Fetal malformations and variations 
Each fetus was exposed to examine for any abnormal findings with 
respect to length, cranium, eyes, palate, limbs, tail, genitals, sex along 
with skeletal and visceral abnormalities of exposed fetuses and data 
is presented in table 3. No statistical difference was observed in the 
frequency of external variations and malformations in LMWGAL-TF 
treated groups as compared to VC group. In the visceral 
examination, hydrocephalous of lateral ventricles of the brain was 
observed in one fetus from LMWGAL-TF (250 mg/kg) group and one 
fetus from LMWGAL-TF (500 mg/kg) group. Hypoplasia of kidneys 
was observed in one fetus from LMWGAL-TF (500 mg/kg) group. 
Retinal folding was observed in one fetus from LMWGAL-TF (500 
mg/kg) group. These incidences of fetal soft tissue or skeletal 
abnormalities are normal variants or minor anomalies and 
considered to be incidental and not treatment related. 
These findings are commonly seen in 20 d. old rat fetuses. As per 
skull, the anomaly is concerned; variation from the ossification 
patterns was seen like unossified, scrambled, poorly and 
incompletely ossified skulls. Such variations were observed in two 
fetuses from the VC group three from LMWGAL-TF (250 mg/kg) 
group, two fetuses from LMWGAL-TF (500 mg/kg) group and 15 
fetuses from LMWGAL-TF (1000 mg/kg) group. These were 
classified as normal variants. Poor and incomplete ossifications of 
sternebrae were also seen in 17 fetuses from VC, 13 from LMWGAL-
TF (250 mg/kg) group, 19 from LMWGAL-TF (500 mg/kg) group 
and 14 from LMWGAL-TF (1000 mg/kg) group. Unossified 
sternebrae were also encountered in all dose groups like 12 fetuses 
in VC, 16 in LMWGAL-TF (250 mg/kg) group, 10 in LMWGAL-TF 
(500 mg/kg) and 4 in LMWGAL-TF (1000 mg/kg). These were all 
classified as normal variants. Poor, incomplete and unossified 
cervical, lumbar, sacral and caudal vertebrae were observed in VC 
and LMWGAL-TF (250 mg/kg) group. Minor anomalies like split, 
rudimentary, dumbbell shaped, asymmetrical, dumbbell shaped, 
extra, misshapen and agenesis of sternebrae were seen in all dose 
groups. These anomalies were observed in 29 fetuses from VC, 31 
fetuses LMWGAL-TF (250 mg/kg) group, 28 from LMWGAL-TF (500 
mg/kg) group and 26 fetuses from LMWGAL-TF (1000 mg/kg) dose 
group. Minor anomalies in ribs like rudimentary, wavy, extra, 
accessory, asymmetrical, nodulated, undulated ribs were observed 
in 30 fetuses from VC, 51 fetuses from LMWGAL-TF, 42 fetuses from 
LMWGAL-TF (500 mg/kg) and 43 fetuses from LMWGAL-TF (1000 
mg/kg) group. Dumbbell/asymmetrical, dumbbell shaped, split, 
asymmetrical, misshapen and fused vertebrae (thoracic and sacral) 
were observed in 7 fetuses from VC, 14 fetuses from LMWGAL-TF 
(250 mg/kg), 16 from LMWGAL-TF (500 mg/kg) and 14 fetuses 
from LMWGAL-TF (1000 mg/kg) group. One fetus from LMWGAL-TF 
(1000 mg/kg) group was observed with misshapen forelimb fingers.  
In general, the skeletal examination did not show any major 
abnormalities which could have caused any functional damage to 
these fetuses, if allowed to grow in the normal course. The 
abnormalities could be considered as the variations which occur 
during development but are repaired and normalized during the 
normal course of development. 
DISCUSSION  
The prenatal developmental toxicity study provides general 
information concerning effects of exposure to the developing 
organism during the gestational period. Developmental toxicity 
studies cover any detrimental effect produced by exposures to 
developing organisms during embryonic stages of development. 
Such lesions can be either irreversible or reversible. Teratological 
studies use the investigations on maternal, embryonic and fetal 
toxicity.  
The present study, for the first time, evaluated the LMWGAL based 
standardized extract of fenugreek seeds, LMWGAL-TF, for prenatal 
developmental toxicity during the gestational period (prenatal 
exposure, GD 5 through GD 19) on maternal and fetus development. 
The LMWGAL-TF was studied at 3 dose levels, namely 250, 500 and 
1000 mg/kg. 
In the present study, LMWGAL-TF was found to be safe on prenatal 
exposure with the no-observed-adverse-effect-level (NOAEL) of 
1000 mg/kg/day. In the past, there have been inconsistent reports 
on reproductive toxicity on crude extract of fenugreek seeds on 
prenatal exposure in rabbit [31], mice [32-34] and rats [31, 35] with 
one case study in human [36]. On the other hand, fenugreek seed 
extract was reported to be safe during pregnancy period [37, 38]. 
However, these reports utilized whole and crude extract with 
unknown composition and not standardized to any marker 
compounds. Furthermore, the toxicity of crude extract may not be 
directly correlated to purified or standardized extracts. For example, 
a well-known sweetener, steviol glycosides (SGs) of Stevia rebaudiana 
leaves, did not show reproductive toxicity in rats [39] whereas crude 
stevia leaf extracts showed renal and cardiovascular adverse effects 
with reduced fertility in male and female rats [40-44].  
Toxic constituents of some plants may contribute to birth defects 
[45]. The prenatal exposure to LMWGAL-TF during gestational days 
(GD5 through GD19), did not cause any toxic birth defects effects in 
terms of weight (body, gravid uterine), food intake, hematology, or 
biochemical parameters. Pregnancy rate is the proportion of mated 
pairs that have produced at least one pregnancy within a fixed 
period where pregnancy is determined by the earliest available 
evidence that fertilization has occurred. There was no maternal 
mortality observed during the gestational period in pregnant rats. 
Maternal parameters related to pregnancy rate are maternal deaths 
during pregnancy, females with the viable fetus (%) and females 
with resorption (%). The numbers of utereal implantations in the 
left and right arms of the uterus were counted in LMWGAL-TF 
treated all dams. A number of resorptions and implantation affect 
litter size per dam. There was no significant change in a total 
number of implantation in terms of pre and post implantation loss 
after LMWGAL-TF exposure. LMWGAL-TF treated groups did not 
show any dose dependent early and late resorption in any dam. 
These findings suggest normal fertilization process with LMWGAL-
TF exposure in the gestational period in rats. 
LMWGAL-TF treated dams did not show adverse effects in terms of a 
number of fetuses and sex ratio of fetuses. The mean live fetal 
weights of male and female fetuses from LMWGAL-TF (500 and 
1000 mg/kg) treated group were significantly higher as compared to 
VC group and is considered as incidental and not considered to be 
biologically significant since this significant change is not 
comparable with other fetal data observed. The incidence of normal 
fetuses observed in this study was 100% in control group and in all 
treatment groups. There were no any external abnormalities 
observed in the study. There were some visceral and skeletal 
abnormalities found in control as well as LMWGAL-TF treated 
groups. In general, there were no major abnormalities which could 
have caused any functional damage to the fetuses, if allowed to grow 
in the normal course.  
Thus, at NOAEL of LMWGAL-TF for prenatal oral exposure during 
the gestational period was found to be greater than or equal to 1000 
mg/kg/day. Human equivalent dose (HED) can be derived from 
NOAEL by using USFDA guidance for Industry [46]. Considering 
NOAEL of 1000 mg/kg in pregnant female rats, HED is almost 9.7 g 
considering the human weight of 60 kg and this HED is much higher 
than efficacy doses that are reported in male volunteers [22].  
CONCLUSION 
In conclusion, LMWGAL-TF did not produce overt signs maternal 
toxicity, or signs of embryo–fetal toxicity and found well-tolerated 
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during the gestation period. Therefore, a dose of 1000 mg/kg can be 
considered as the NOAEL of LMWGAL-TF for prenatal oral exposure 
in rats. This safety information during a gestational period in 
pregnant female rats will form an important basis for the clinical 
development of LMWGAL-TF as a safe dietary supplement or 
botanical agent for female specific applications. 
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